BCYC Stock Analysis: Buy, Sell, or Hold?
BCYC - Bicycle Therapeutics plc American Depositary Shares
$4.35
0.14 (3.33%)
▲
5d:
+8.48%
30d:
+1.16%
90d:
-11.22%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 14, 2026
Get Alerted When BCYC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BCYC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: BCYC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: BCYC is currently trading at $4.35, which is considered slightly high relative to its 30-day fair value range of $4.00 to $4.42.
Technical Outlook: Technically, BCYC is in a strong downtrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: BCYC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.62 (+190.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCYC is in a strong downtrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: BCYC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.62 (+190.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.00 -
$4.42
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 190.2% below Wall St target ($12.62)
Trading Range Analysis
30-Day Trading Range
$4.00 -
$4.42
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.92
Resistance Level
$4.40
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.05
Wall Street Target
$12.63
(+190.2%)
Revenue Growth (YoY)
-91.1%
Share & Embed Analysis
Last updated: July 02, 2026 10:40 PM ET
Data refreshes hourly during market hours. Next update: 11:40 PM
Data refreshes hourly during market hours. Next update: 11:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCYC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Lee
SELL
1716 shares
2026-04-06
Travis Alvin Thompson
SELL
102 shares
2026-04-06
Jennifer Scott Perry
SELL
370 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
